Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #189 on Portola Phramaceuticals (PTLA)
DewDiligence
01/10/20 5:13 PM
#190 RE: H2R #189
Fourth quarter Andexxa net sales in the U.S. were impacted primarily by two factors: • A $5 million gross to net adjustment due to a return reserve for short-dated product. The Company expects this to be mitigated going forward by its current longer-dated, 36-month product, which began shipping in November 2019. • Flat quarter over quarter demand due to a decrease in utilization, primarily in tier 1 accounts. While physician demand remains strong, the Company believes that in certain of these accounts, hospital pharmacies curtailed use of Andexxa following drug utilization reviews in an effort to manage pharmacy budgets. Following this reduction, re-ordering patterns are stabilizing in many of these accounts.